DRG Market Assessment reports

In April 2017, Truxima (rituximab), Celltrion’s biosimilar of Roche’s MabThera, became the first oncology monoclonal antibody (MAb) biosimilar to enter the European market. In this series, we…

Inflectra (infliximab-dyyb), Pfizer/Celltrion’s Remicade biosimilar, became the first monoclonal antibody biosimilar to enter the U.S. market in late November 2016. In this series, we track…

The success of biologics will greatly depend on payers because they are the ones who determine which products gain formulary access and preferential reimbursement. Understanding the factors that…

The regulatory and market access landscape for biosimilars is constantly evolving. For a company seeking to develop a biosimilar for multiple markets, keeping track of the similarities and…

Biosimilars│Emerging Biosimilars│Inflectra │U.S. Wave 1 is the first installment of a three-wave, syndicated report series, tracking physician perception and uptake of Pfizer/Celltrion’s…

Biologics in oncology, immunology, nephrology and endocrinology generated over $70 billion in 2015, nearly all attributed to branded biologics. As more branded agents lose patent protection and…

Abstract Introduction: The Emerging Biosimilars Overview offers extensive coverage of the global biosimilar development landscape. We track over 350 currently available and novel biosimilar…

Biosimilars | Emerging Biosimilars | Oncology: Zarxio Launch Tracking (US) Wave 3 is the third and final installment in a series of syndicated reports designed to track physician perception and…

A number of filgrastim and epoetin alfa biosimilars are available to European oncologists, and since 2015, U.S. oncologists have had access to Zarxio—the first biosimilar launched in the United…

The uptake of biosimilar erythropoiesis-stimulating agents (ESAs) varies from country to country, as well as by drug and manufacturer. European nephrologists have been able to prescribe ESAs to…

Abstract Introduction: With a growing number of biosimilars in development and the launch of the first FDA-approved products in 2015, biosimilars are set to gain an increasing share of the…

Inflectra/Remsima (Germany) Wave 3 is the third in a series of syndicated reports designed to track physician perception and uptake of Hospira’s Inflectra and Mundipharma’s Remsima, two…